Big Pharma and the cost of developing COVID-19 drugs and vaccines
From cheap coronavirus treatments to the use of blood plasma, we look at options available to low-income nations.
The race to develop vaccines and treatments for the coronavirus pandemic is entering a crucial stage with large-scale trials under way.
But with seemingly little oversight on pricing, some experts are concerned that pharmaceutical companies could end up charging way too much for COVID-19 treatments.
And if rich nations corner the market on vaccines, they could also limit accessibility for low-income countries.
Plus, Twitter found itself at the centre of a hack that compromised its high-profile users’ accounts. We talk to the CEO of a Silicon Valley company that uses biometrics and artificial intelligence to protect accounts.
Published On 25 Jul 2020